ArriVent BioPharma, Inc. (AVBP) stock
AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.69−0.87 (-7.53%)
Close on Nov 17, 2026Market cap $527.10MP/E –Yield –
ArriVent BioPharma total assets
Total assets on the balance sheet at the end of each period.
ArriVent BioPharma's total assets was $394.72M at Jun 30, 2026. For fiscal 2025 it was $333.17M, up 21.2% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $333.17M | +21.2% |
| FY2024 | Dec 31, 2024 | $274.94M | +68.6% |
| FY2023 | Dec 31, 2023 | $163.10M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $394.72M | +46.5% |
| Q1 FY2026 | Mar 31, 2026 | $349.30M | +62.1% |
| Q4 FY2025 | Dec 31, 2025 | $333.17M | +21.2% |
| Q3 FY2025 | Sep 30, 2025 | $326.56M | +11.6% |
| Q2 FY2025 | Jun 30, 2025 | $269.51M | -12.7% |
| Q1 FY2025 | Mar 31, 2025 | $215.50M | -34.3% |
| Q4 FY2024 | Dec 31, 2024 | $274.94M | +68.6% |
| Q3 FY2024 | Sep 30, 2024 | $292.71M | – |
| Q2 FY2024 | Jun 30, 2024 | $308.86M | – |
| Q1 FY2024 | Mar 31, 2024 | $327.84M | – |
| Q4 FY2023 | Dec 31, 2023 | $163.10M | – |
See a number that looks wrong?